Literature DB >> 9482853

A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription.

H Xiao1, Y Tao, J Greenblatt, R G Roeder.   

Abstract

Replication of HIV-1 requires the viral Tat protein, which increases the extent of transcription elongation by RNA polymerase II after activation at the single viral long terminal repeat (LTR) promoter. This effect of Tat on transcription requires Tat interactions with a 5' region (TAR) in nascent transcripts as well as Tat-specific cofactors. The present study identifies a cellular protein, TIP30, that interacts with Tat and with an SRB-containing RNA polymerase II complex both in vivo and in vitro. Coexpression of TIP30 specifically enhances transactivation by Tat in transfected cells, and immunodepletion of TIP30 from nuclear extracts abolishes Tat-activated transcription without affecting Tat-independent transcription. These results implicate TIP30 as a specific coactivator that may enhance formation of a Tat-RNA polymerase II holoenzyme complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482853      PMCID: PMC19278          DOI: 10.1073/pnas.95.5.2146

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.

Authors:  F Wu; J Garcia; D Sigman; R Gaynor
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

2.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator.

Authors:  P Nelbock; P J Dillon; A Perkins; C A Rosen
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

4.  HIV-1 Tat protein trans-activates transcription in vitro.

Authors:  R A Marciniak; B J Calnan; A D Frankel; P A Sharp
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

5.  c-myc reverses neu-induced transformed morphology by transcriptional repression.

Authors:  T C Suen; M C Hung
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

6.  Inhibition of in vivo and in vitro transcription by monoclonal antibodies prepared against wheat germ RNA polymerase II that react with the heptapeptide repeat of eukaryotic RNA polymerase II.

Authors:  N E Thompson; T H Steinberg; D B Aronson; R R Burgess
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

7.  Cloning and characterization of human TAF20/15. Multiple interactions suggest a central role in TFIID complex formation.

Authors:  A Hoffmann; R G Roeder
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

8.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

9.  Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro.

Authors:  D I Chasman; J Leatherwood; M Carey; M Ptashne; R D Kornberg
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

10.  The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.

Authors:  M Emerman; M Guyader; L Montagnier; D Baltimore; M A Muesing
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  30 in total

1.  Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis.

Authors:  S Whitman; X Wang; R Shalaby; E Shtivelman
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  The structure of the negative transcriptional regulator NmrA reveals a structural superfamily which includes the short-chain dehydrogenase/reductases.

Authors:  D K Stammers; J Ren; K Leslie; C E Nichols; H K Lamb; S Cocklin; A Dodds; A R Hawkins
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

3.  The transcriptome of prematurely aging yeast cells is similar to that of telomerase-deficient cells.

Authors:  Isabelle Lesur; Judith L Campbell
Journal:  Mol Biol Cell       Date:  2004-01-12       Impact factor: 4.138

4.  Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Genomic expression responses to DNA-damaging agents and the regulatory role of the yeast ATR homolog Mec1p.

Authors:  A P Gasch; M Huang; S Metzner; D Botstein; S J Elledge; P O Brown
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

6.  Overexpression of CC3/TIP30 is associated with HER-2/neu status in breast cancer.

Authors:  Dao-Hai Zhang; Lee Lee Wong; Lee Kian Tai; Evelyn S C Koay; Robert E Hewitt
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

7.  Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein.

Authors:  Pejman Rahimian; Johnny J He
Journal:  J Neurovirol       Date:  2016-05-12       Impact factor: 2.643

8.  Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

9.  Evidence for regulation of long terminal repeat transcription by Wnt transcription factor TCF-4 in human astrocytic cells.

Authors:  Bethany Wortman; Nune Darbinian; Bassel E Sawaya; Kamel Khalili; Shohreh Amini
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Inhibition of nuclear import by the proapoptotic protein CC3.

Authors:  Frank W King; Emma Shtivelman
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.